{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:17:42Z","timestamp":1788254262965,"version":"build-2803163510"},"reference-count":62,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Cancer vaccination addresses four distinct problems: preventing oncogenic infection, intercepting premalignant clones, clearing molecular residual disease, and treating established cancer. This hypothesis framework proposes seven sequential gates for antigen-defined, HLA-restricted T-cell vaccines: tumor specificity, natural peptide\u2013HLA presentation, population coverage, persistence under immune selection, selective T-cell recognition, manufacturability, and randomized clinical benefit. The proposed architecture combines a pre-manufactured core of validated shared antigens with a personalized shell when shared targets do not cover the tumor or the patient\u2019s HLA type. Current evidence supports restraint. Individualized mRNA neoantigen therapy with pembrolizumab produced a recurrence-free-survival signal in a randomized phase 2b melanoma trial, whereas a 20-antigen shared cassette produced immunodominant responses toward encoded TP53 epitopes rather than the KRAS neoantigens carried by the tumors. No quantitative coverage or persistence score is presented because the required population frequencies and persistence measurements cannot be supplied reliably from the published record. Four falsifiable predictions define the experiments needed to test presentation-first selection, antigen persistence, escape-route independence, and biomarker-directed treatment. The framework is therefore a research agenda, not a validated decision tool.<\/jats:p>","DOI":"10.3390\/vaccines14090753","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:31:13Z","timestamp":1788251473000},"page":"753","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From Universal Aspiration to Precision Immunization: A Hypothesis Framework for Antigen-Defined, HLA-Restricted Cancer Vaccines"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0513-0336","authenticated-orcid":false,"given":"Sarfaraz K.","family":"Niazi","sequence":"first","affiliation":[{"name":"College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA 99202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/jnci\/djp288","article-title":"Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study","volume":"101","author":"Chang","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV Vaccination and the Risk of Invasive Cervical Cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41568-025-00820-z","article-title":"Recent advances in therapeutic cancer vaccines","volume":"25","author":"Zaidi","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s43018-021-00210-y","article-title":"Targeting public neoantigens for cancer immunotherapy","volume":"2","author":"Pearlman","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41577-024-01091-9","article-title":"Vax-Innate: Improving therapeutic cancer vaccines by modulating T cells and the tumour microenvironment","volume":"25","author":"Baharom","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Niazi, S.K. (2026). Sequence-Anchored Shared Tumor-Specific Epitopes for Pre-Manufactured HLA-Matched mRNA Cancer Vaccine Libraries: A Pan-Cancer Framework. Biomolecules, 16.","DOI":"10.3390\/biom16071015"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41587-024-02420-y","article-title":"A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy","volume":"43","author":"Huber","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","article-title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: A register-based observational study","volume":"398","author":"Falcaro","year":"2021","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41591-024-02851-9","article-title":"A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: Phase 1 trial interim results","volume":"30","author":"Rappaport","year":"2024","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/s41591-025-04182-9","article-title":"Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: A phase 1b\/2 trial","volume":"32","author":"Willis","year":"2026","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41586-024-07752-y","article-title":"Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy","volume":"632","author":"Sultan","year":"2024","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/2159-8290.CD-20-0377","article-title":"An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth","volume":"11","author":"Lam","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s43018-025-00966-7","article-title":"Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: A phase 1 trial","volume":"6","author":"Saxena","year":"2025","journal-title":"Nat. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1158\/1078-0432.CCR-19-3517","article-title":"A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I\/IIa Clinical Trial","volume":"26","author":"Kloor","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.cell.2020.11.004","article-title":"Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors","volume":"183","author":"Roudko","year":"2020","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","article-title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: The phase 1 AMPLIFY-201 trial","volume":"30","author":"Pant","year":"2024","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","article-title":"A neoantigen vaccine generates antitumour immunity in renal cell carcinoma","volume":"639","author":"Braun","year":"2025","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","article-title":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: Phase 1 AMPLIFY-201 trial final results","volume":"31","author":"Wainberg","year":"2025","journal-title":"Nat. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1470-2045(13)70510-2","article-title":"Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, phase 3 trial","volume":"15","author":"Butts","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S1470-2045(16)00099-1","article-title":"Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Vansteenkiste","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.18.02031","article-title":"Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer","volume":"37","author":"Gulley","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annonc.2023.07.006","article-title":"Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1","volume":"34","author":"Besse","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Narayan, R., Olsson, N., Wagar, L.E., Medeiros, B.C., Meyer, E., Czerwinski, D., Khodadoust, M.S., Zhang, L., Schultz, L., and Davis, M.M. (2019). Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0219547"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"eaba4380","DOI":"10.1126\/scitranslmed.aba4380","article-title":"Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine","volume":"14","author":"Gigoux","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1038\/s41467-022-33746-3","article-title":"The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma","volume":"13","author":"Bauer","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2018","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Arrieta-Bola\u00f1os, E., Hern\u00e1ndez-Zaragoza, D.I., and Barquera, R. (2023). An HLA map of the world: A comparison of HLA frequencies in 200 worldwide populations reveals diverse patterns for class I and class II. Front. Genet., 14.","DOI":"10.3389\/fgene.2023.866407"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"23667","DOI":"10.1038\/s41598-025-06704-4","article-title":"High resolution class I HLA-A, -B, and -C diversity in Eastern and Southern African populations","volume":"15","author":"Banjoko","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","article-title":"Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction","volume":"183","author":"Wells","year":"2020","journal-title":"Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.immuni.2017.02.007","article-title":"Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction","volume":"46","author":"Abelin","year":"2017","journal-title":"Immunity"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nbt.4313","article-title":"Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification","volume":"37","author":"Busby","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: Improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41586-025-08586-y","article-title":"Clonal driver neoantigen loss under EGFR TKI and immune selection pressures","volume":"639","author":"Reading","year":"2025","journal-title":"Nature"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41591-022-02163-w","article-title":"Persistent mutation burden drives sustained anti-tumor immune responses","volume":"29","author":"Niknafs","year":"2023","journal-title":"Nat. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e2338612","DOI":"10.1001\/jamanetworkopen.2023.38612","article-title":"Eligibility for Human Leukocyte Antigen\u2013Based Therapeutics by Race and Ethnicity","volume":"6","author":"Olivier","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_48","first-page":"D783","article-title":"Allele frequency net database (AFND) 2020 update: Gold-standard data classification, open access genotype data and new query tools","volume":"48","author":"McCabe","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.humimm.2013.06.025","article-title":"Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry","volume":"74","author":"Gragert","year":"2013","journal-title":"Hum. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines, A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e156211","DOI":"10.1172\/JCI156211","article-title":"Messenger RNA vaccines for cancer immunotherapy: Progress promotes promise","volume":"132","author":"Huff","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA","volume":"23","author":"Buckstein","year":"2005","journal-title":"Immunity"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1093\/nar\/gkq347","article-title":"Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation","volume":"38","author":"Anderson","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1126\/science.aaa3828","article-title":"A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells","volume":"348","author":"Carreno","year":"2015","journal-title":"Science"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","article-title":"MHC-II neoantigens shape tumour immunity and response to immunotherapy","volume":"574","author":"Alspach","year":"2019","journal-title":"Nature"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s41586-025-10004-2","article-title":"Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC","volume":"651","author":"Sahin","year":"2026","journal-title":"Nature"},{"key":"ref_58","unstructured":"ClinicalTrials.gov (2026, July 10). A Clinical Study of Intismeran Autogene (V940) Plus Pembroli-zumab in People with High-Risk Melanoma (V940-001), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05933577."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e2500008","DOI":"10.1200\/OA-25-00008","article-title":"Three-Year Update of a Randomized Phase IIb Study of the Individualized Neoantigen Therapy Intismeran Autogene (mRNA-4157, V940) Plus Pembrolizumab Versus Pembrolizumab in Resected Melanoma","volume":"3","author":"Carlino","year":"2026","journal-title":"JCO Oncol. Adv."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Khattak, A., Carlino, M.S., Meniawy, T., Ansstas, G., Taylor, M.H., Kim, K.B., McKean, M., Long, G.V., Sullivan, R.J., and Faries, M. (J. Clin. Oncol., 2026). Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study, J. Clin. Oncol., epub ahead of printing.","DOI":"10.1200\/JCO-26-00835"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","article-title":"Autogene cevumeran with or without atezolizumab in advanced solid tumors: A phase 1 trial","volume":"31","author":"Lopez","year":"2025","journal-title":"Nat. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","article-title":"Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: A phase 1\/2 trial","volume":"30","author":"Yarchoan","year":"2024","journal-title":"Nat. Med."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/9\/753\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:43:45Z","timestamp":1788252225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/9\/753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":62,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["vaccines14090753"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14090753","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]}}}